High-Concentration rhGAA Composition With Chaperone Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapies for Pompe disease, such as recombinant α-glucosidase, face challenges with enzyme instability, aggregation, and inefficient tissue uptake, particularly at high concentrations, which limits their therapeutic efficacy.
Innovation Solution
Combining recombinant human α-glucosidase (rhGAA) with an Active Site-Specific Chaperone (ASSC) like 1-deoxynojirimycin (DNJ) at high concentrations, up to 250 mg/mL, stabilizes the enzyme conformation and reduces aggregation, enhancing its stability and tissue delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If recombinant human α-glucosidase is administered at high concentrations to improve therapeutic efficacy, then the treatment effectiveness increases, but the enzyme undergoes aggregation and loses stability
Solution Approach 1:
The patent introduces a chaperone protein as an intermediary substance that binds to recombinant human α-glucosidase and prevents aggregation. This chaperone acts as a mediator between the enzyme and the physiological environment, maintaining enzyme stability at high concentrations by preventing intermolecular interactions that lead to aggregation.
Solution Approach 2:
The patent creates a composite therapeutic composition consisting of recombinant human α-glucosidase combined with chaperone proteins. This composite formulation allows the enzyme to maintain stability and solubility at high concentrations that would otherwise cause aggregation, thereby improving therapeutic efficacy while maintaining enzyme integrity.
2Stability of the object's composition
If recombinant human α-glucosidase is administered at high concentrations to reduce aggregation, then enzyme stability improves, but tissue uptake efficiency decreases
Solution Approach 1:
The patent optimizes the concentration parameters of both the recombinant human α-glucosidase and the chaperone proteins within specific ranges (enzyme: 1-100 mg/mL, chaperone: 1-1000 μM). By carefully controlling these parameters, the formulation achieves a balance where enzyme stability is maintained through high concentration without exceeding the threshold that would impair tissue uptake efficiency.
3Quantity of substance
If enzyme concentration is increased to improve therapeutic effect, then treatment efficacy improves, but aggregation increases reducing delivery efficiency
Solution Approach 1:
The chaperone protein serves as a protective intermediary that surrounds and stabilizes individual enzyme molecules, preventing them from aggregating even at high concentrations. This intermediary layer ensures that increased enzyme concentration translates to improved therapeutic effect without the harmful aggregation that would otherwise reduce delivery efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of rhGAA with DNJ maintains enzyme stability and activity, allowing for higher concentrations without aggregation, improving tissue uptake and therapeutic efficacy in treating Pompe disease.
Implementation Method 1
Combining recombinant human α-glucosidase (rhGAA) with an Active Site-Specific Chaperone (ASSC) like 1-deoxynojirimycin (DNJ) at high concentrations, up to 250 mg/mL, stabilizes the enzyme conformation and reduces aggregation
Data Source
AI summary
The present application provides for compositions comprising high concentrations of acid α-glucosidase in combination with an active site-specific chaperone for the acid α-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid α-glucosidase enzyme formulation.